Title :

Imaging necrosis during treatment is associated with worse survival in eortc 26101 study

Author(s) :

Nowosielski, Martha [Auteur]
Gorlia, Thierry [Auteur]
Bromberg, Jacoline E. C. [Auteur]
Sahm, Felix [Auteur]
Harting, Inga [Auteur]
Kickingereder, Philipp [Auteur]
Brandes, Alba A. [Auteur]
Taphoorn, Martin J. B. [Auteur]
Taal, Walter [Auteur]
Domont, Julien [Auteur]
Idbaih, Ahmed [Auteur]
Campone, Mario [Auteur]
Clement, Paul M. [Auteur]
Weller, Michael [Auteur]
Fabbro, Michel [Auteur]
Le Rhun, Emilie [Auteur]
Platten, Michael [Auteur]
Golfinopoulos, Vassilis [Auteur]
Van Den Bent, Martin J. [Auteur]
Bendszus, Martin [Auteur]
Wick, Wolfgang [Auteur]

Journal title :

Neurology

Abbreviated title :

Neurology

Publication date :

2019-05-10

ISSN :

1526-632X

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

OBJECTIVE: Imaging necrosis on MRI scans was assessed and compared to outcome measures of the European Organisation for Research and Treatment of Cancer 26101 phase III trial that compared single-agent lomustine with ...
Show more >OBJECTIVE: Imaging necrosis on MRI scans was assessed and compared to outcome measures of the European Organisation for Research and Treatment of Cancer 26101 phase III trial that compared single-agent lomustine with lomustine plus bevacizumab in patients with progressive glioblastoma. METHODS: MRI in this post hoc analysis was available for 359 patients (lomustine = 127, lomustine + bevacizumab = 232). First, imaging necrosis at baseline being formally measurable (>10 x 10 mm, given 2 slices) was assessed. At weeks 6 and 12 of treatment, it was analyzed whether this necrosis remained stable or increased >25% calculated by 2 perpendicular diameters or whether necrosis developed de novo. Univariate and multivariate associations of baseline necrosis with overall survival (OS) and progression-free survival (PFS) were tested by log-rank test. Hazard ratios (HR) with 95% confidence interval were calculated by Cox model. RESULTS: Imaging necrosis at baseline was detected in 191 patients (53.2%) and was associated with worse OS and PFS in univariate, but not in multivariate analysis. Baseline necrosis was predictive for OS in the lomustine-only group (HR 1.46, p = 0.018). At weeks 6 and 12 of treatment, increase of baseline necrosis and de novo necrosis were strongly associated with worse OS and PFS in univariate and multivariate analysis (PFS both p < 0.001, OS univariate p < 0.001, multivariate p = 0.0046). CONCLUSION: Increase of and new development of imaging necrosis during treatment is a negative prognostic factor for patients with progressive glioblastoma. These data call for consideration of integrating the assessment of imaging necrosis as a separate item into the MRI response assessment criteria.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

INSERM
Université de Lille

Collections :

• Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192

Submission date :

2022-06-15T13:57:44Z